These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 32737030)
21. Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma. Cao C; Yu R; Gong W; Liu D; Zhang X; Fang Y; Xia Y; Zhang W; Gao Q Aging (Albany NY); 2021 Nov; 13(22):24686-24709. PubMed ID: 34837690 [TBL] [Abstract][Full Text] [Related]
22. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients. Wu Q; Zhang N; Xie X BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827 [TBL] [Abstract][Full Text] [Related]
23. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. Jamieson A; Huvila J; Chiu D; Thompson EF; Scott S; Salvador S; Vicus D; Helpman L; Gotlieb W; Kean S; Samouelian V; Köbel M; Kinloch M; Parra-Harran C; Offman S; Grondin K; Irving J; Lum A; Senz J; Leung S; McConechy MK; Plante M; Kommoss S; Huntsman DG; Talhouk A; Gilks CB; McAlpine JN Mod Pathol; 2023 Apr; 36(4):100085. PubMed ID: 36788084 [TBL] [Abstract][Full Text] [Related]
24. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol. Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023 [TBL] [Abstract][Full Text] [Related]
29. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331 [TBL] [Abstract][Full Text] [Related]
30. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Cosgrove CM; Tritchler DL; Cohn DE; Mutch DG; Rush CM; Lankes HA; Creasman WT; Miller DS; Ramirez NC; Geller MA; Powell MA; Backes FJ; Landrum LM; Timmers C; Suarez AA; Zaino RJ; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ Gynecol Oncol; 2018 Jan; 148(1):174-180. PubMed ID: 29132872 [TBL] [Abstract][Full Text] [Related]
31. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features. Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer. Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529 [TBL] [Abstract][Full Text] [Related]
33. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. Sengal AT; Patch AM; Snell CE; Smith DS; Leung SCY; Talhouk A; Williams ED; McAlpine JN; Pollock PM Clin Cancer Res; 2020 Sep; 26(17):4569-4580. PubMed ID: 32414751 [TBL] [Abstract][Full Text] [Related]
34. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis. Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355 [TBL] [Abstract][Full Text] [Related]
35. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts. Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303 [TBL] [Abstract][Full Text] [Related]
36. Spatial Cancer-Immune Phenotypes Predict Shorter Recurrence-Free Survival in the No Specific Molecular Profile Molecular Subtype of Endometrial Carcinoma. de Biase D; Lenzi J; Ceccarelli C; Maloberti T; Grillini M; Coadǎ CA; Zamagni C; De Iaco P; Perrone AM; Santini D; Köbel M; Lee CH; Tallini G; De Leo A Mod Pathol; 2024 Sep; 38(1):100624. PubMed ID: 39326496 [TBL] [Abstract][Full Text] [Related]
37. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups. Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998 [TBL] [Abstract][Full Text] [Related]